Several lines of evidence have suggested that growth hormone (GH), and its local effector insulin-like growth factor-l (IGF-I), promote physiological cardiac growth. GH and/or IGF-I treatment have also been demonstrated to increase myocardial contractility and cardiac output in experimental models of cardiac failure. Similarly, insulin administered with glucose and potassium (GIK therapy) can decrease the rate of ischemic cell death following acute myocardial infarction. However, the effects of GH therapy in human subjects is still inconclusive, and recent reports in animal models suggest that long-term IGF-I treatment may not be beneficial because chronic IGF-I stimulation can induce aspects of pathological hypertrophy. Therefore, the development of therapeutic strategies for maintaining cardiac function in the failing heart could benefit from a better understanding of the molecular distinction between normal cardiac growth and pathological cardiac hypertrophy. We have shown that IGF-1 and insulin activate the phosphatidylinositol 3-kinase/Akt signaling pathway in cardiac myocytes and vascular cells. We have also shown that activation of this pathway is an essential step in mediating the IGF- and insulin-induced survival and growth signals in cardiac myocytes. Therefore, this grant will focus on mechanisms of myocardial remodeling in mice that have gain-of-function or loss-of-function genetic alterations at this and subsequent signaling steps. We propose to analyze myocardial remodeling and failure in inducible Akt transgenic and knockout mouse models (Aim 1); assess coronary vasculature growth and regression during myocardial growth and regression (Aim 2); analyze the role of the Akt-regulated transcription factors in controlling heart growth and function (Aim 3); and perform genomic and proteomic analyses of Akt and forkhead-mediated remodeling in the heart (Aim 4). These studies should provide a better understanding of the mechanism that regulate adaptive and maladaptive remodeling, and provide new insights about the development and treatment of heart failure.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
1R01HL077774-01A1
Application #
6924052
Study Section
Cardiac Contractility, Hypertrophy, and Failure Study Section (CCHF)
Program Officer
Buxton, Denis B
Project Start
2005-03-01
Project End
2010-02-28
Budget Start
2005-03-01
Budget End
2006-02-28
Support Year
1
Fiscal Year
2005
Total Cost
$403,750
Indirect Cost
Name
Boston University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
604483045
City
Boston
State
MA
Country
United States
Zip Code
02118
Araki, Satoshi; Izumiya, Yasuhiro; Hanatani, Shinsuke et al. (2012) Akt1-mediated skeletal muscle growth attenuates cardiac dysfunction and remodeling after experimental myocardial infarction. Circ Heart Fail 5:116-25
Shimano, Masayuki; Ouchi, Noriyuki; Shibata, Rei et al. (2010) Adiponectin deficiency exacerbates cardiac dysfunction following pressure overload through disruption of an AMPK-dependent angiogenic response. J Mol Cell Cardiol 49:210-20
Higuchi, Akiko; Ohashi, Koji; Shibata, Rei et al. (2010) Thiazolidinediones reduce pathological neovascularization in ischemic retina via an adiponectin-dependent mechanism. Arterioscler Thromb Vasc Biol 30:46-53
Oshima, Yuichi; Ouchi, Noriyuki; Shimano, Masayuki et al. (2009) Activin A and follistatin-like 3 determine the susceptibility of heart to ischemic injury. Circulation 120:1606-15
Higuchi, Akiko; Ohashi, Koji; Kihara, Shinji et al. (2009) Adiponectin suppresses pathological microvessel formation in retina through modulation of tumor necrosis factor-alpha expression. Circ Res 104:1058-65
Ikeda, Yasumasa; Ohashi, Koji; Shibata, Rei et al. (2008) Cyclooxygenase-2 induction by adiponectin is regulated by a sphingosine kinase-1 dependent mechanism in cardiac myocytes. FEBS Lett 582:1147-50
Shibata, Rei; Skurk, Carsten; Ouchi, Noriyuki et al. (2008) Adiponectin promotes endothelial progenitor cell number and function. FEBS Lett 582:1607-12
Papanicolaou, Kyriakos N; Izumiya, Yasuhiro; Walsh, Kenneth (2008) Forkhead transcription factors and cardiovascular biology. Circ Res 102:16-31
Izumiya, Yasuhiro; Bina, Holly A; Ouchi, Noriyuki et al. (2008) FGF21 is an Akt-regulated myokine. FEBS Lett 582:3805-10
Ouchi, Noriyuki; Oshima, Yuichi; Ohashi, Koji et al. (2008) Follistatin-like 1, a secreted muscle protein, promotes endothelial cell function and revascularization in ischemic tissue through a nitric-oxide synthase-dependent mechanism. J Biol Chem 283:32802-11

Showing the most recent 10 out of 27 publications